|
DE3321826A1
(de)
|
1983-06-15 |
1984-12-20 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
13(alpha)-alkylgonane, deren herstellung und diese enthaltende pharmazeutische praeparate
|
|
ES8502612A1
(es)
|
1983-06-15 |
1985-02-01 |
Schering Ag |
Procedimiento para la preparacion de 13a-alquilgonanos
|
|
US4780461A
(en)
|
1983-06-15 |
1988-10-25 |
Schering Aktiengesellschaft |
13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
|
|
US4742000A
(en)
|
1986-05-02 |
1988-05-03 |
University Of Chicago |
Antibody to human progesterone receptor and diagnostic materials and methods
|
|
DE3630030A1
(de)
|
1986-09-01 |
1988-03-03 |
Schering Ag |
13(alpha)-alkylgonan-(delta)(pfeil hoch)9(pfeil hoch)(pfeil hoch)((pfeil hoch)(pfeil hoch)1(pfeil hoch)1(pfeil hoch))(pfeil hoch)-5,10-epoxide
|
|
US4774236A
(en)
|
1986-09-17 |
1988-09-27 |
Research Triangle Institute |
17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
|
|
IE60780B1
(en)
|
1987-01-23 |
1994-08-10 |
Akzo Nv |
New 11-aryl steroid derivatives
|
|
DE3822770A1
(de)
|
1988-07-01 |
1990-01-04 |
Schering Ag |
13-alkyl-11ss-phenylgonane
|
|
US5283190A
(en)
|
1989-07-31 |
1994-02-01 |
Traish Adbulmaged M |
Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use
|
|
DE4008584A1
(de)
|
1990-03-15 |
1991-09-26 |
Schering Ag |
Verfahren zur herstellung von zwischenprodukten fuer die antigestagensynthese (onapristonsynthese)
|
|
US5141961A
(en)
|
1991-06-27 |
1992-08-25 |
Richrdson-Vicks Inc. |
Process for solubilizing difficulty soluble pharmaceutical actives
|
|
MX9301121A
(es)
|
1992-03-02 |
1993-09-01 |
Schering Ag |
Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
|
|
CN1053450C
(zh)
|
1992-11-19 |
2000-06-14 |
北京第三制药厂 |
17位取代11β－取代芳香基－4,9－雌甾二烯类化合物的全合成法
|
|
DE4332283A1
(de)
|
1993-09-20 |
1995-04-13 |
Jenapharm Gmbh |
Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
|
|
NZ295365A
(en)
|
1994-10-24 |
1999-07-29 |
Schering Ag |
Competitive progesterone antagonists for regulating female fertility as required
|
|
US5759577A
(en)
|
1995-01-17 |
1998-06-02 |
American Home Products Corporation |
Controlled release of steroids from sugar coatings
|
|
US6900193B1
(en)
|
1996-05-01 |
2005-05-31 |
The United States Of America As Represented By The Department Of Health And Human Services |
Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
|
|
IL122740A
(en)
|
1997-01-15 |
2003-09-17 |
Akzo Nobel Nv |
16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
|
|
US5962444A
(en)
|
1998-05-29 |
1999-10-05 |
Research Triangle Institute |
17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
|
|
US6537584B1
(en)
|
1999-11-12 |
2003-03-25 |
Macromed, Inc. |
Polymer blends that swell in an acidic environment and deswell in a basic environment
|
|
WO2001089566A1
(en)
|
2000-05-19 |
2001-11-29 |
Genentech, Inc. |
Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
|
|
US6750015B2
(en)
|
2000-06-28 |
2004-06-15 |
Kathryn B. Horwitz |
Progesterone receptor-regulated gene expression and methods related thereto
|
|
UY26966A1
(es)
|
2000-10-18 |
2002-06-20 |
Schering Ag |
Uso de antiprogestinas para la inducción de apoptosis en una célula
|
|
US7381976B2
(en)
|
2001-03-13 |
2008-06-03 |
Triton Thalassic Technologies, Inc. |
Monochromatic fluid treatment systems
|
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
|
US7105642B2
(en)
|
2001-08-03 |
2006-09-12 |
Cell Signalling Technology, Inc. |
Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof
|
|
US20040121304A1
(en)
|
2001-12-21 |
2004-06-24 |
Ulrike Fuhrmann |
Method for screening for progesterone receptor isoform-specific ligands and for tissue-selective progesterone receptor ligands
|
|
AU2004217988C1
(en)
|
2003-02-28 |
2010-06-03 |
Southwest Foundation For Biomedical Research |
Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
|
|
US20040265371A1
(en)
|
2003-06-25 |
2004-12-30 |
Looney Dwayne Lee |
Hemostatic devices and methods of making same
|
|
US7247625B2
(en)
*
|
2003-10-09 |
2007-07-24 |
Wyeth |
6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators
|
|
JP5017109B2
(ja)
|
2004-07-09 |
2012-09-05 |
ザ・ポピュレイション・カウンシル，インコーポレイテッド |
プロゲステロン受容体モジュレーターを含有する徐放性組成物
|
|
CA2580795A1
(en)
|
2004-09-22 |
2006-04-06 |
Tripath Imaging, Inc. |
Methods and compositions for evaluating breast cancer prognosis
|
|
CA2604218A1
(en)
|
2005-04-20 |
2006-10-26 |
Pfizer Limited |
Pyrazole derivatives as progesterone receptor antagonists
|
|
WO2007078599A2
(en)
|
2005-12-16 |
2007-07-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Functional arrays for high throughput characterization of gene expression regulatory elements
|
|
US20070167971A1
(en)
|
2006-01-17 |
2007-07-19 |
Raymond Huey |
Devices and methods for promoting the formation of blood clots in esophageal varices
|
|
US20070166372A1
(en)
|
2006-01-19 |
2007-07-19 |
Mai De Ltd. |
Preparation of solid coprecipitates of amorphous valsartan
|
|
WO2007098381A2
(en)
|
2006-02-17 |
2007-08-30 |
Janssen Pharmaceutica N.V. |
11-phosphorous steroid derivatives useful as progesterone receptor modulators
|
|
DE102006054535A1
(de)
|
2006-11-15 |
2008-05-21 |
Bayer Schering Pharma Aktiengesellschaft |
Progesteronrezeptorantagonisten
|
|
CN101668739A
(zh)
|
2007-04-24 |
2010-03-10 |
帝斯曼知识产权资产管理有限公司 |
用于制造前维生素d的光化学方法
|
|
CA2596204C
(en)
|
2007-08-07 |
2019-02-26 |
Historx, Inc. |
Method and system for determining an optimal dilution of a reagent
|
|
WO2009025759A1
(en)
|
2007-08-17 |
2009-02-26 |
Progenics Pharmaceuticals (Nevada), Inc. |
Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
|
|
WO2009048993A2
(en)
*
|
2007-10-12 |
2009-04-16 |
Novartis Ag |
Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
|
|
EP2075246A1
(en)
|
2007-12-27 |
2009-07-01 |
M. J. Institute of Research |
A process for preparation of amorphous form of atorvastatin hemi-calcium salt
|
|
CA2712005C
(en)
|
2008-02-05 |
2014-04-15 |
Harbor Biosciences, Inc. |
Pharmaceutical solid state forms
|
|
TW201002736A
(en)
|
2008-04-28 |
2010-01-16 |
Repros Therapeutics Inc |
Compositions and methods for treating progesterone-dependent conditions
|
|
TWI539953B
(zh)
|
2008-04-28 |
2016-07-01 |
瑞波若斯治療學公司 |
用於治療乳癌之組成物和方法
|
|
WO2010110086A1
(ja)
|
2009-03-27 |
2010-09-30 |
株式会社小松製作所 |
作業車両の省燃費制御装置および作業車両の省燃費制御方法
|
|
WO2010126590A1
(en)
|
2009-04-27 |
2010-11-04 |
Cold Spring Harbor Laboratory |
Ptp1b inhibitors
|
|
US20110003753A1
(en)
|
2009-06-01 |
2011-01-06 |
Samuel Waxman Cancer Research Foundation |
COMPOSITIONS AND METHODS FOR DISRUPTING THE FUNCTION OF THE TRANSCRIPTIONAL REPRESSOR COMPONENT Sin3A-PAH2 DOMAIN TO INDUCE DIFFERENTIATION AND GROWTH INHIBITION IN BREAST CANCER
|
|
BR112012000750B1
(pt)
|
2009-07-15 |
2021-05-25 |
Cti Biopharma Corp. |
sal citrato cristalino, composição farmacêutica compreendendo o referido sal e uso do mesmo
|
|
US20110293511A1
(en)
*
|
2009-09-29 |
2011-12-01 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
US8261855B2
(en)
*
|
2009-11-11 |
2012-09-11 |
Flanders Electric, Ltd. |
Methods and systems for drilling boreholes
|
|
JP5965844B2
(ja)
|
2009-12-15 |
2016-08-10 |
バインド セラピューティックス インコーポレイテッド |
高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
|
|
MX2012010327A
(es)
*
|
2010-03-22 |
2012-11-16 |
Repros Therapeutics Inc |
Composiciones y metodos para la administracion no toxica de antiprogestinas.
|
|
EP3702460A1
(en)
|
2010-11-12 |
2020-09-02 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
MX354210B
(es)
|
2010-12-16 |
2018-02-16 |
Celgene Corp |
Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
|
|
AU2011349464B2
(en)
|
2010-12-20 |
2016-07-07 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAS
|
|
US20140079722A1
(en)
|
2011-03-09 |
2014-03-20 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
SI2683384T1
(sl)
|
2011-03-11 |
2016-05-31 |
Celgene Corporation |
Metode zdravljenja raka z uporabo 3-(5-amino-2-metil-4-okso-4H-kinazolin-3-il)-piperidin-2,6-diona
|
|
US9618512B2
(en)
|
2011-04-15 |
2017-04-11 |
J-Pharma Co., Ltd. |
Biomarker for breast cancer
|
|
EP3026064B1
(en)
|
2011-05-13 |
2018-10-17 |
Ganymed Pharmaceuticals GmbH |
Antibodies for treatment of cancer expressing claudin 6
|
|
US20130029953A1
(en)
*
|
2011-07-28 |
2013-01-31 |
Klaus Nickisch |
Progesterone antagonists
|
|
AU2012318618B2
(en)
|
2011-10-04 |
2017-01-12 |
Invivis Pharmaceuticals Inc. |
Methods and systems for identifying and treating anti-progestin sensitive tumors
|
|
WO2013086379A2
(en)
|
2011-12-08 |
2013-06-13 |
Fundacion Sales |
Methods and compositions for treating antiprogestin-resistant cancers
|
|
US20130338016A1
(en)
|
2012-04-17 |
2013-12-19 |
Vala Sciences, Inc. |
Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis
|
|
WO2013162776A1
(en)
|
2012-04-27 |
2013-10-31 |
Lange Carol |
Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
|
|
US20150241432A1
(en)
|
2012-07-24 |
2015-08-27 |
Cedar-Sinai Medical Center |
Novel method to detect resistance to chemotherapy in patients with lung cancer
|
|
US20150320795A1
(en)
|
2012-12-13 |
2015-11-12 |
Roy JOSEE |
Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
|
|
US9193757B2
(en)
|
2013-03-12 |
2015-11-24 |
Arno Therapeutics, Inc. |
Onapristone polymorphic forms and methods of use
|
|
US20140363425A1
(en)
|
2013-03-13 |
2014-12-11 |
J. Dinny Graham |
Systems and methods for identifying cancers having activated progesterone receptors
|
|
US9096641B2
(en)
|
2013-06-05 |
2015-08-04 |
Evestra, Inc. |
Imidazolyl progesterone antagonists
|
|
CN103483449A
(zh)
|
2013-08-20 |
2014-01-01 |
东北农业大学 |
两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用
|
|
RU2016133175A
(ru)
|
2014-04-08 |
2018-05-08 |
Арно Терапьютикс, Инк. |
Системы и способы для идентификации подтипов рецепторов к прогестерону
|
|
RU2017112748A
(ru)
|
2014-11-17 |
2018-12-19 |
Арно Терапьютикс, Инк. |
Композиции онапристона пролонгированного действия и способы
|
|
EP3273983B1
(en)
|
2015-03-23 |
2021-05-05 |
Evestra, Inc. |
Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
|
|
AU2016326657B2
(en)
|
2015-09-25 |
2019-10-24 |
Context Biopharma, Inc. |
Methods of making onapristone intermediates
|
|
HK1255104A1
(zh)
|
2015-12-15 |
2019-08-02 |
Context Biopharma Inc. |
无定形的奥那司酮组合物及其制备方法
|
|
US20170266204A1
(en)
|
2016-03-21 |
2017-09-21 |
Arno Therapeutics, Inc. |
Onapristone metabolite compositions and methods
|
|
AU2017260232B2
(en)
|
2016-05-02 |
2024-07-18 |
Abcellera Boston, Inc. |
Anti-Kv1.3 antibodies, and methods of production and use thereof
|
|
WO2018067198A1
(en)
|
2016-10-03 |
2018-04-12 |
The Regents Of The University Of California |
Inhibitory antibodies and methods of use thereof
|